Skip to main content

Table 1 Baseline demographics and disease characteristics

From: Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study

Baseline characteristics mITT population (N = 82)
Median age, years (range) 60.0 (42, 82)
Patient age, n (%)
 ≥65 32 (39.0)
Gender, n (%)
 Male 43 (52.4)
 Female 39 (47.6)
Baseline ECOG performance status, n (%)
 0 26 (31.7)
 1 54 (65.9)
 2 2 (2.4)
Tumor burden increase (screening to pre-dose), n (%) 60 (73.2)
 Median, % 23.1
 Range, % 2.1–317.9
MM subtype at baseline, n (%)
 IgG 40 (48.8)
 IgA 17 (20.7)
 IgD 7 (8.5)
 Others 19 (23.2)
R-ISS stage at baseline, n (%)
 I 23 (28.0)
 II 50 (61.0)
 III 9 (11.0)
High-risk cytogenetic abnormalities 55 (67.1)
 del 17p13 18 (22.0)
 t(4;14) 21 (25.6)
 t(14;16) 5 (6.1)
 1q amplification 53 (64.6)
Creatinine clearance, mL/min, n (%)
 <30 3 (3.7)
 30–<60 15 (18.3)
 ≥60 64 (78.0)
Median time since initial MM diagnosis, years (range) 3.2 (0.2–13.4)
Respond to last regimen (≥PR), n (%) 24 (29.3)
Median prior regimens (range) 5 (1–16)
Prior therapy, n (%)
 Lenalidomide
  Exposed vs refractory 82 (100.0) vs 82 (100.0)
 Bortezomib
  Exposed vs refractory 82 (100.0) vs 82 (100.0)
 Daratumumab
  Exposed vs refractory 23 (28.0) vs 20 (24.4)
 Ixazomib
  Exposed vs refractory 28 (34.1) vs 26 (31.7)
 Carfilzomib
  Exposed vs refractory 6 (7.3) vs 5 (6.1)
 Pomalidomide
  Exposed vs refractory 10 (12.2) vs 9 (11.0)
 Prior ASCT 18 (22.0)
 Prior CAR-T 10 (12.2)
  1. ASCT Autologous stem cell transplantation, CAR Chimeric antigen receptor, ECOG Eastern Cooperative Oncology Group, mITT Modified intent-to-treat, MM Multiple myeloma, R-ISS Revised-International Staging System